Phase II study of high-dose cisplatin, etoposide, and cyclophosphamide for refractory ovarian cancer

J. M. Cain, C. Collins, S. Petersdorf, D. C. Figge, H. K. Tamimi, B. E. Greer, Robert B Livingston, J. B. Schlaerth, I. Golditch

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

OBJECTIVES: A phase II trial of high-dose cyclophosphamide, etoposide, and cisplatin was done. STUDY DESIGN: Forty-eight patients with progressive or persistent disease and previous cisplatin-based chemotherapy and no paclitaxel therapy were entered for treatment on the basis of two cycles of cyclophosphamide (4500 mg/m2), etoposide (750 mg/m2), and cisplatin (120 mg/m2). RESULT: Seventy-four cycles were delivered. Six patients died during treatment (12.5%). Of 28 with measurable disease, there was a 25% response rate and 32% had stable disease. Median time to recurrence and survival were significantly different for minimal versus bulky disease (p = 0.0089, p = 0.0008, log-rank) and for platinum-sensitive versus platinum-resistant disease (p = 0.18, p = 0.0012, log-rank). The number of prior regimens was not correlated with time to progression or survival. CONCLUSION: This study shows little advantage for high-dose protocols except for patients with a response to platinating agents and minimal residual disease.

Original languageEnglish (US)
Pages (from-to)1688-1694
Number of pages7
JournalAmerican Journal of Obstetrics and Gynecology
Volume174
Issue number6
DOIs
StatePublished - 1996
Externally publishedYes

Fingerprint

Etoposide
Ovarian Neoplasms
Cyclophosphamide
Cisplatin
Platinum
Survival
Residual Neoplasm
Paclitaxel
Therapeutics
Recurrence
Drug Therapy

Keywords

  • Cisplatin
  • cyclophosphamide
  • etoposide
  • ovarian cancer

ASJC Scopus subject areas

  • Medicine(all)
  • Obstetrics and Gynecology

Cite this

Cain, J. M., Collins, C., Petersdorf, S., Figge, D. C., Tamimi, H. K., Greer, B. E., ... Golditch, I. (1996). Phase II study of high-dose cisplatin, etoposide, and cyclophosphamide for refractory ovarian cancer. American Journal of Obstetrics and Gynecology, 174(6), 1688-1694. https://doi.org/10.1016/S0002-9378(96)70198-9

Phase II study of high-dose cisplatin, etoposide, and cyclophosphamide for refractory ovarian cancer. / Cain, J. M.; Collins, C.; Petersdorf, S.; Figge, D. C.; Tamimi, H. K.; Greer, B. E.; Livingston, Robert B; Schlaerth, J. B.; Golditch, I.

In: American Journal of Obstetrics and Gynecology, Vol. 174, No. 6, 1996, p. 1688-1694.

Research output: Contribution to journalArticle

Cain, JM, Collins, C, Petersdorf, S, Figge, DC, Tamimi, HK, Greer, BE, Livingston, RB, Schlaerth, JB & Golditch, I 1996, 'Phase II study of high-dose cisplatin, etoposide, and cyclophosphamide for refractory ovarian cancer', American Journal of Obstetrics and Gynecology, vol. 174, no. 6, pp. 1688-1694. https://doi.org/10.1016/S0002-9378(96)70198-9
Cain, J. M. ; Collins, C. ; Petersdorf, S. ; Figge, D. C. ; Tamimi, H. K. ; Greer, B. E. ; Livingston, Robert B ; Schlaerth, J. B. ; Golditch, I. / Phase II study of high-dose cisplatin, etoposide, and cyclophosphamide for refractory ovarian cancer. In: American Journal of Obstetrics and Gynecology. 1996 ; Vol. 174, No. 6. pp. 1688-1694.
@article{652a02e0b4644ed9b59df02e10f5819d,
title = "Phase II study of high-dose cisplatin, etoposide, and cyclophosphamide for refractory ovarian cancer",
abstract = "OBJECTIVES: A phase II trial of high-dose cyclophosphamide, etoposide, and cisplatin was done. STUDY DESIGN: Forty-eight patients with progressive or persistent disease and previous cisplatin-based chemotherapy and no paclitaxel therapy were entered for treatment on the basis of two cycles of cyclophosphamide (4500 mg/m2), etoposide (750 mg/m2), and cisplatin (120 mg/m2). RESULT: Seventy-four cycles were delivered. Six patients died during treatment (12.5{\%}). Of 28 with measurable disease, there was a 25{\%} response rate and 32{\%} had stable disease. Median time to recurrence and survival were significantly different for minimal versus bulky disease (p = 0.0089, p = 0.0008, log-rank) and for platinum-sensitive versus platinum-resistant disease (p = 0.18, p = 0.0012, log-rank). The number of prior regimens was not correlated with time to progression or survival. CONCLUSION: This study shows little advantage for high-dose protocols except for patients with a response to platinating agents and minimal residual disease.",
keywords = "Cisplatin, cyclophosphamide, etoposide, ovarian cancer",
author = "Cain, {J. M.} and C. Collins and S. Petersdorf and Figge, {D. C.} and Tamimi, {H. K.} and Greer, {B. E.} and Livingston, {Robert B} and Schlaerth, {J. B.} and I. Golditch",
year = "1996",
doi = "10.1016/S0002-9378(96)70198-9",
language = "English (US)",
volume = "174",
pages = "1688--1694",
journal = "American Journal of Obstetrics and Gynecology",
issn = "0002-9378",
publisher = "Mosby Inc.",
number = "6",

}

TY - JOUR

T1 - Phase II study of high-dose cisplatin, etoposide, and cyclophosphamide for refractory ovarian cancer

AU - Cain, J. M.

AU - Collins, C.

AU - Petersdorf, S.

AU - Figge, D. C.

AU - Tamimi, H. K.

AU - Greer, B. E.

AU - Livingston, Robert B

AU - Schlaerth, J. B.

AU - Golditch, I.

PY - 1996

Y1 - 1996

N2 - OBJECTIVES: A phase II trial of high-dose cyclophosphamide, etoposide, and cisplatin was done. STUDY DESIGN: Forty-eight patients with progressive or persistent disease and previous cisplatin-based chemotherapy and no paclitaxel therapy were entered for treatment on the basis of two cycles of cyclophosphamide (4500 mg/m2), etoposide (750 mg/m2), and cisplatin (120 mg/m2). RESULT: Seventy-four cycles were delivered. Six patients died during treatment (12.5%). Of 28 with measurable disease, there was a 25% response rate and 32% had stable disease. Median time to recurrence and survival were significantly different for minimal versus bulky disease (p = 0.0089, p = 0.0008, log-rank) and for platinum-sensitive versus platinum-resistant disease (p = 0.18, p = 0.0012, log-rank). The number of prior regimens was not correlated with time to progression or survival. CONCLUSION: This study shows little advantage for high-dose protocols except for patients with a response to platinating agents and minimal residual disease.

AB - OBJECTIVES: A phase II trial of high-dose cyclophosphamide, etoposide, and cisplatin was done. STUDY DESIGN: Forty-eight patients with progressive or persistent disease and previous cisplatin-based chemotherapy and no paclitaxel therapy were entered for treatment on the basis of two cycles of cyclophosphamide (4500 mg/m2), etoposide (750 mg/m2), and cisplatin (120 mg/m2). RESULT: Seventy-four cycles were delivered. Six patients died during treatment (12.5%). Of 28 with measurable disease, there was a 25% response rate and 32% had stable disease. Median time to recurrence and survival were significantly different for minimal versus bulky disease (p = 0.0089, p = 0.0008, log-rank) and for platinum-sensitive versus platinum-resistant disease (p = 0.18, p = 0.0012, log-rank). The number of prior regimens was not correlated with time to progression or survival. CONCLUSION: This study shows little advantage for high-dose protocols except for patients with a response to platinating agents and minimal residual disease.

KW - Cisplatin

KW - cyclophosphamide

KW - etoposide

KW - ovarian cancer

UR - http://www.scopus.com/inward/record.url?scp=0030037730&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030037730&partnerID=8YFLogxK

U2 - 10.1016/S0002-9378(96)70198-9

DO - 10.1016/S0002-9378(96)70198-9

M3 - Article

C2 - 8678128

AN - SCOPUS:0030037730

VL - 174

SP - 1688

EP - 1694

JO - American Journal of Obstetrics and Gynecology

JF - American Journal of Obstetrics and Gynecology

SN - 0002-9378

IS - 6

ER -